Sarepta Therapeutics, Inc. (SRPT)
Largest Insider Buys in Sector
SRPT Stock Price History Chart
SRPT Stock Performance
About Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 …
Insider Activity of Sarepta Therapeutics, Inc.
Over the last 12 months, insiders at Sarepta Therapeutics, Inc. have bought $4.96M and sold $12.54M worth of Sarepta Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Sarepta Therapeutics, Inc. have bought $6.22M and sold $15.86M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Chambers Michael Andrew (director) — $4.96M.
The last purchase of 37,038 shares for transaction amount of $4.96M was made by Chambers Michael Andrew (director) on 2024‑08‑16.
List of Insider Buy and Sell Transactions, Sarepta Therapeutics, Inc.
| 2024-08-30 | Sale | Chief Financial Officer | 5,985 0.0063% | $137.36 | $822,100 | -8.29% | ||
| 2024-08-16 | director | 37,038 0.0404% | $133.80 | $4.96M | 0.00% | |||
| 2024-06-25 | Sale | Chief Tech Ops Officer | 3,898 0.0043% | $163.23 | $636,271 | -19.52% | ||
| 2024-06-25 | Sale | EVP, General Counsel | 38,957 0.0421% | $161.61 | $6.3M | -19.52% | ||
| 2024-06-24 | Sale | Chief Tech Ops Officer | 7,859 0.0083% | $163.08 | $1.28M | -22.33% | ||
| 2024-05-02 | Sale | Chief Customer Officer | 3,635 0.0041% | $140.00 | $508,900 | -2.62% | ||
| 2024-03-11 | Sale | director | 761 0.0008% | $122.93 | $93,550 | +4.27% | ||
| 2024-03-08 | Sale | director | 15,000 0.0159% | $123.25 | $1.85M | +1.84% | ||
| 2024-03-05 | Sale | director | 3,135 0.0033% | $122.96 | $385,480 | +2.85% | ||
| 2024-03-01 | Sale | Chief Financial Officer | 1,200 0.0013% | $128.30 | $153,960 | -1.94% | ||
| 2024-03-01 | Sale | EVP, General Counsel | 2,000 0.0021% | $125.34 | $250,680 | -1.94% | ||
| 2024-03-01 | Sale | Chief Tech Ops Officer | 2,000 0.0021% | $128.84 | $257,676 | -1.94% | ||
| 2023-11-03 | President & CEO | 25,225 0.0275% | $79.36 | $2M | +59.43% | |||
| 2023-11-03 | director | 50,000 0.0542% | $78.81 | $3.94M | +59.43% | |||
| 2023-08-14 | director | 9,979 0.0104% | $109.47 | $1.09M | +7.21% | |||
| 2023-08-11 | director | 23,686 0.0254% | $108.05 | $2.56M | +11.44% | |||
| 2023-08-10 | director | 34,867 0.0374% | $106.15 | $3.7M | +13.50% | |||
| 2023-08-04 | Sale | director | 15,000 0.0163% | $106.72 | $1.6M | +13.87% | ||
| 2022-11-17 | Sale | director | 858 0.0011% | $109.92 | $94,311 | +10.87% | ||
| 2022-08-19 | 40,110 0.0459% | $108.20 | $4.34M | +11.83% |
Insider Historical Profitability
| Chambers Michael Andrew | director | 284034 0.2974% | $110.10 | 5 | 0 | +11.83% |
| HAYWOOD GEORGE WEAVER | 8213717 8.599% | $110.10 | 16 | 0 | <0.0001% | |
| INGRAM DOUGLAS S | President & CEO | 390307 0.4086% | $110.10 | 7 | 0 | +20.1% |
| Barry Richard | director | 140000 0.1466% | $110.10 | 7 | 3 | +25.36% |
| BEHRENS M KATHLEEN | director | 130517 0.1366% | $110.10 | 6 | 2 | +55.61% |
Institutional Investor Ownership
| The Vanguard Group | $1.14B | 9.31 | 8.8M | -0.23% | -$2.64M | 0.02 | |
| BlackRock | $771.63M | 6.31 | 5.96M | -4.05% | -$32.55M | 0.02 | |
| Janus Henderson | $633.17M | 5.18 | 4.89M | -8.5% | -$58.82M | 0.32 | |
| Capital International Investors | $623.68M | 5.1 | 4.82M | +1.6% | +$9.84M | 0.13 | |
| Avoro Capital Advisors Llc | $562.43M | 4.6 | 4.34M | 0% | +$0 | 6.74 |